2 Majority of patients were treated with standard of care 1,2,n,o Summary of medication at baseline (N=3533) 1,2 Select CV and CKD baseline characteristics (N=3533) 1,2 n At baseline patients in FLOW were receiving standard-of-care background therapy, including a maximum tolerated label dose of a RAAS-blocking agent including an ACE inhibitor or an ARB, unless such treatment was contraindicated or not tolerated
Interesting finding Semaglutide may slow the progression of osteoarthritis (OA) independently of weight loss
G., Aman, Y., Figueroa, D., Morevati, M., Lee, H
The honest answer: We dont know yet
Everything is designed around a deep understanding of members real lives and goals, so support feels personal, connected, and consistent wherever someone meets WeightWatchers. Kate Wadia, founder and chief creative officer, Mrs&Mr said: We set out to reclaim WeightWatchers rightful place as a pioneer and innovator in the rapidly changing world of weight loss